NO993804L - Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav - Google Patents

Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav

Info

Publication number
NO993804L
NO993804L NO993804A NO993804A NO993804L NO 993804 L NO993804 L NO 993804L NO 993804 A NO993804 A NO 993804A NO 993804 A NO993804 A NO 993804A NO 993804 L NO993804 L NO 993804L
Authority
NO
Norway
Prior art keywords
ions
hedgehog proteins
pharmaceutical mixtures
pharmaceutical
mixtures
Prior art date
Application number
NO993804A
Other languages
English (en)
Norwegian (no)
Other versions
NO993804D0 (no
Inventor
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98114851A external-priority patent/EP0987028A1/de
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO993804D0 publication Critical patent/NO993804D0/no
Publication of NO993804L publication Critical patent/NO993804L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
NO993804A 1998-08-07 1999-08-06 Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav NO993804L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98114851A EP0987028A1 (de) 1998-08-07 1998-08-07 Pharmazeutische Zusammensetzung von Hedgehog-Proteinen und deren Verwendung
EP98116734 1998-09-03

Publications (2)

Publication Number Publication Date
NO993804D0 NO993804D0 (no) 1999-08-06
NO993804L true NO993804L (no) 2000-02-08

Family

ID=26149508

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993804A NO993804L (no) 1998-08-07 1999-08-06 Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav

Country Status (14)

Country Link
US (1) US6207718B1 (de)
EP (1) EP0978285B1 (de)
JP (1) JP3567103B2 (de)
CN (1) CN1244429A (de)
AT (1) ATE310531T1 (de)
AU (1) AU761341B2 (de)
CA (1) CA2279743C (de)
DE (1) DE69928472T2 (de)
DK (1) DK0978285T3 (de)
ES (1) ES2253851T3 (de)
HU (1) HUP9902655A3 (de)
IL (1) IL131238A (de)
MA (1) MA26667A1 (de)
NO (1) NO993804L (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028454A1 (en) * 1997-11-28 1999-06-10 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
ES2252886T3 (es) * 1998-04-30 2006-05-16 Curis, Inc. Conjugado de proteinas de erizo activo, proceso para su produccion y uso.
EP1025861A1 (de) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2280925A1 (en) * 1999-07-29 2001-01-29 Bernard Charles Sherman Stabilized cefuroxime axetil
WO2001082994A1 (en) * 2000-04-28 2001-11-08 Curis, Inc. Methods and reagents for tissue engineering of cartilage in vitro
EP1947116B1 (de) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung
WO2004087870A2 (en) * 2003-03-25 2004-10-14 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US20070148144A1 (en) * 2005-10-27 2007-06-28 Mason James M Gene-enhanced tissue engineering
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
US7678764B2 (en) * 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
DE602008004351D1 (de) * 2007-06-29 2011-02-17 Atrm Llc Flüssige proteinformulierungen mit gdf-5 zur verwendung bei erhöhten temperaturen
JP5323832B2 (ja) * 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にgdf−5を含むタンパク質製剤
BRPI0911048A2 (pt) * 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
WO2011034421A1 (en) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (de) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Hemmung von TNIK zur Behandlung von Darmkrebs
US9295720B2 (en) 2010-08-27 2016-03-29 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2465928A1 (de) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Behandlung von Th17-vermittelten Krankheiten
WO2015070031A1 (en) 2013-11-08 2015-05-14 University Of Virginia Patent Foundation Compositions and methods for treating melanoma
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
US12570981B2 (en) 2016-03-21 2026-03-10 University Of Virginia Patent Foundation Genetically modified mouse with conditional deletion of LRP1 in oligodendrocytes
AU2017363131B2 (en) * 2016-11-16 2020-01-16 Aivita Biomedical, Inc. Use of cell membrane-bound signaling factors
CA3082896A1 (en) * 2017-11-16 2019-05-23 Aivita Biomedical, Inc. Use of cell membrane-bound signaling factors
WO2025263459A1 (ja) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 バイオ医薬品組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148901A (en) 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5156623A (en) 1990-04-16 1992-10-20 Olympus Optical Co., Ltd. Sustained release material and method of manufacturing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
EP0741783B1 (de) 1993-12-30 2009-03-18 President And Fellows Of Harvard College "hedgehog-like" proteine von wirbeltieren, die embryonale strukturen induzieren
JPH09509574A (ja) 1994-02-25 1997-09-30 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 脊索によって発現されるヘッジホッグ、Vhh−1、の脊椎動物相同体をコードするDNA、及びこれらの使用
US5663390A (en) 1996-08-29 1997-09-02 Libbey-Owens-Ford Co. Method of producing organo indium chlorides
JPH10194987A (ja) * 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0947201B1 (de) * 1998-02-04 2006-06-28 Curis, Inc. Pharmazeutische Zusammensetzungen von Hedgehog-Proteinen und deren Verwendung
EP0953575A1 (de) * 1998-04-30 1999-11-03 Boehringer Mannheim Gmbh Aktives Hedgehog-Protein-Konjugat, Verfahren zur Herstellung und Verwendung
ES2252886T3 (es) * 1998-04-30 2006-05-16 Curis, Inc. Conjugado de proteinas de erizo activo, proceso para su produccion y uso.

Also Published As

Publication number Publication date
EP0978285A1 (de) 2000-02-09
US6207718B1 (en) 2001-03-27
IL131238A (en) 2005-07-25
EP0978285B1 (de) 2005-11-23
CA2279743C (en) 2005-05-10
CN1244429A (zh) 2000-02-16
ATE310531T1 (de) 2005-12-15
JP2000063283A (ja) 2000-02-29
DE69928472D1 (de) 2005-12-29
HK1025740A1 (en) 2000-11-24
CA2279743A1 (en) 2000-02-07
IL131238A0 (en) 2001-01-28
JP3567103B2 (ja) 2004-09-22
HU9902655D0 (en) 1999-10-28
HUP9902655A2 (hu) 2000-08-28
HUP9902655A3 (en) 2000-12-28
ES2253851T3 (es) 2006-06-01
NO993804D0 (no) 1999-08-06
DK0978285T3 (da) 2006-03-27
AU761341B2 (en) 2003-06-05
DE69928472T2 (de) 2006-08-10
AU4344899A (en) 2000-03-02
MA26667A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
NO993804L (no) Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav
DK1028741T3 (da) Regulering af epitelvæv ved hjælp af hedgehog-lignende polypeptider og formuleringer og anvendelser, som er relateret hertil
DK0699104T3 (da) Fremgangsmåde til underkritisk tørring af aerogeler
BR0017013A (pt) Composições de antibiótico azalìdeo
NO20005421L (no) Stabile oksiderende brom formuleringer, fremgangsmåter ved fremstilling derav og fremgangsmåter ved anvendelse for mikrobiologisk vekst kontroll
AU636738B2 (en) Nematicidal compositions
BR9814104A (pt) Compostos benzeno substituìdos, processo parasua preparação e composições herbicidas edesfolhantes contendo os mesmos
NO975773L (no) Fremgangsmåter for stabil innarbeiding av substanser i törre, skummede glass-grunnmasser, og sammensetninger oppnådd derved
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
ECSP034442A (es) Mezclas de polisacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen
ATE448833T1 (de) Haarbehandlungsmittel
MY105503A (en) Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
NO883554L (no) Fremgangsmaate til isolering av basiske proteiner fra proteinblandinger som inneholder slike basiske proteiner.
BR9910920A (pt) Composição não inflamável, e, processos de limpeza e de revestimento
HK1047032A1 (zh) 处理解开的蛋白质表现方法的方法及产品
KR860000025A (ko) 콩단백질 수용액의 처리방법
DE69318136D1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
NO953644L (no) Konsentrerte rengjöringsblandinger
BR9807183A (pt) Mistura sólida e processos para o controle de vegetação indesejada e para a preparação de formulações herbicidas
PT1411971E (pt) Utilizacao de pentraxina longa ptx3 para o tratamento de infertilidade feminina
SE8502540D0 (sv) Stable dentifrice containing dextranase
DK0497724T3 (da) Middel til desintegration af galdesten
TR199901897A2 (xx) İspençiyari kirpi proteinleri terkibi ve bunun kullanılması.
IS5355A (is) Nýstárleg ferli, er fela í sér valmöguleika á rúmafstöðu atóma og atómhópa, til að smíða gabapentín-hliðstæður
JPH10248911A (ja) 消臭剤・除菌剤組成物

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application